Studies on secondary prophylaxis regimens performed in the Mediterranean region for visceral leishmaniasis in HIV+ patients.

<p>Studies on secondary prophylaxis regimens performed in the Mediterranean region for visceral leishmaniasis in HIV+ patients.</p

Estimated sensitivity and specificity of diagnostic tests based on antibody detection for VL in HIV-infected patients, using a random effects model and their respective 95% confidence intervals [50].

<p>Data for antigen detection in urine <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0003021#pntd.0003021-Riera1" target="_blank">[56]</a>, <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0003021#pntd.0003021-Vilaplana1" target="_blank">[55]</a>. Abbreviations: CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; IFAT, indirect fluorescent antibody test.</p

Therapy for visceral leishmaniasis in HIV-coinfected patients in the Mediterranean area.

<p>Evidence-based recommendation. <b>Strength of recommendation:</b><b>A</b> = Good evidence to support a recommendation for use; <b>B</b> = Moderate evidence to support a recommendation for use; <b>C</b> = Poor evidence to support a recommendation; <b>D</b> = Moderate evidence to support a recommendation against use; <b>E</b> = Good evidence to support a recommendation against use.</p><p><b>Quality of evidence</b>: <b>I</b> = Evidence from one or more randomized clinical trials; <b>II</b> = Evidence from one or more well-designed clinical trials, without randomization; from cohort or case-controlled analytic studies (preferably from >1 center); from multiple time series; or from dramatic results from uncontrolled experiments; <b>III</b> = Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0003021#pntd.0003021-Khan1" target="_blank">[77]</a>, <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0003021#pntd.0003021-Kish1" target="_blank">[78]</a>. Abbreviations: IM, intramuscular; IV, intravenous; po, per os.</p

Cardiac Cystic Echinococcosis series with n≥10 reported in the last 10 years in the literature.

<p>Cardiac Cystic Echinococcosis series with n≥10 reported in the last 10 years in the literature.</p

Computed tomography showing IVC cyst (arrow) and multiple CE pulmonary embolisms (arrowheads) (patient 7).

<p>Computed tomography showing IVC cyst (arrow) and multiple CE pulmonary embolisms (arrowheads) (patient 7).</p

Inferior vena cava Cystic Echinococcosis cases reported in the literature^*.

<p>Note: ALB: Albendazole; CE: cystic echinococcosis; CT scan: computed tomography scan F: female; IVC: inferior vena cava; IDC: intravascular disseminated coagulation; M: male; MRI: Magnetic Resonance Imaging ND: not defined; RA: right atrium; w: weeks.</p><p>*Only intraluminal invasion. Cases with vena cava compression and vena cava wall involvement are excluded.</p

Excel spreadsheet including, in separate sheets, all numerical values used for Figs 1, 2, 3, 4 and S1.

Excel spreadsheet including, in separate sheets, all numerical values used for Figs 1, 2, 3, 4 and S1.</p

Regional distribution of autochthonous <i>Leishmania infantum</i> infections in humans and animals in European countries reported in the scientific literature and by the ministries of health of some countries, between 2009 and 2020.

Regional distribution of autochthonous Leishmania infantum infections in humans and animals in European countries reported in the scientific literature and by the ministries of health of some countries, between 2009 and 2020.</p

Number of outbreaks and cases of <i>Leishmania</i> infection in dogs and wildlife in Europe, reported to the World Organization for Animal Health (OIE-WAHIS) between 2005 and 2020.

Number of outbreaks and cases of Leishmania infection in dogs and wildlife in Europe, reported to the World Organization for Animal Health (OIE-WAHIS) between 2005 and 2020.</p

Annual cumulative incidence per 100,000 population of autochthonous human cutaneous leishmaniasis in European countries between 2005 and 2020.

Data based on cases reported to the WHO Global Health Observatory Data Repository.</p